Blog

Filament Health

Filament Health Issued Second U.S. Patent and Reports Q1 Results

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a second patent by the United States Patent and Trademark Office (USPTO) for the extraction and standardization of natural psilocybin and associated psychedelic compounds. The patent describes essential technology for transforming variable […]

Jason Hein Researches Design, Development, and Efficiencies – Podcast Episode #4

On the fourth episode of the Psychedelic Invest Podcast, Bruce Eckfeldt welcomes Jason Hein. Jason is an Associate Professor at The University of British Columbia and the CEO of Telescope Innovations. During this conversation, no chemistry topic is off-limits. The pair talk about developing compounds, delivering them, and the importance of monitoring every single output. […]

Revive Therapeautics

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral […]

Albert Labs Granted Health Canada License

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines for mental health treatments, is pleased to report it has been granted a Health Canada License dated 05-05-2022 for its research and production facility in Burnaby, Canada. This approval permits the legal possession, […]